Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Galsulfase (Naglazyme) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.

2.

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.

Brunelli MJ, Atallah ÁN, da Silva EM.

Cochrane Database Syst Rev. 2016 Mar 4;3:CD009806. doi: 10.1002/14651858.CD009806.pub2. Review.

PMID:
26943923
3.

[Mucopolysaccharidosis: clinical features, diagnosis and management].

Suarez-Guerrero JL, Gómez Higuera PJ, Arias Flórez JS, Contreras-García GA.

Rev Chil Pediatr. 2016 Jul-Aug;87(4):295-304. doi: 10.1016/j.rchipe.2015.10.004. Epub 2015 Nov 21. Review. Spanish.

4.

Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Vairo F, Federhen A, Baldo G, Riegel M, Burin M, Leistner-Segal S, Giugliani R.

Appl Clin Genet. 2015 Oct 30;8:245-55. doi: 10.2147/TACG.S68650. eCollection 2015. Review.

5.

Lacritin and other autophagy associated proteins in ocular surface health.

Karnati R, Talla V, Peterson K, Laurie GW.

Exp Eye Res. 2016 Mar;144:4-13. doi: 10.1016/j.exer.2015.08.015. Epub 2015 Aug 25. Review.

6.

Therapy for mucopolysaccharidosis VI: (Maroteaux-Lamy syndrome) present status and prospects.

Giugliani R, Herber S, Lapagesse L, de Pinto C, Baldo G.

Pediatr Endocrinol Rev. 2014 Sep;12 Suppl 1:152-8. Review.

PMID:
25345097
7.

Current and potential therapeutic strategies for mucopolysaccharidoses.

Noh H, Lee JI.

J Clin Pharm Ther. 2014 Jun;39(3):215-24. doi: 10.1111/jcpt.12136. Epub 2014 Feb 25. Review.

PMID:
24612142
8.

Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.

Braunlin E, Orchard PJ, Whitley CB, Schroeder L, Reed RC, Manivel JC.

Cardiovasc Pathol. 2014 May-Jun;23(3):145-51. doi: 10.1016/j.carpath.2014.01.001. Epub 2014 Jan 10. Review.

PMID:
24508139
9.

Treatment of lysosomal storage diseases: recent patents and future strategies.

Ortolano S, Viéitez I, Navarro C, Spuch C.

Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):9-25. Review.

PMID:
24433521
10.

Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.

Muenzer J.

Mol Genet Metab. 2014 Feb;111(2):63-72. doi: 10.1016/j.ymgme.2013.11.015. Epub 2013 Dec 11. Review.

11.

Neurologic manifestations of inherited disorders of connective tissue.

Debette S, Germain DP.

Handb Clin Neurol. 2014;119:565-76. doi: 10.1016/B978-0-7020-4086-3.00037-0. Review.

PMID:
24365320
12.

Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders.

Parker EI, Xing M, Moreno-De-Luca A, Harmouche E, Terk MR.

Br J Radiol. 2014 Jan;87(1033):20130467. doi: 10.1259/bjr.20130467. Epub 2013 Nov 14. Review. Erratum in: Br J Radiol. 2014 Mar;87(1035):20149002.

13.

Attenuated osteoarticular phenotype of type VI mucopolysaccharidosis: a report of four patients and a review of the literature.

Jurecka A, Zakharova E, Malinova V, Voskoboeva E, Tylki-Szymańska A.

Clin Rheumatol. 2014 May;33(5):725-31. doi: 10.1007/s10067-013-2423-z. Epub 2013 Nov 13. Review.

14.

Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation.

Opoka-Winiarska V, Jurecka A, Emeryk A, Tylki-Szymańska A.

Osteoarthritis Cartilage. 2013 Dec;21(12):1813-23. doi: 10.1016/j.joca.2013.08.001. Epub 2013 Aug 13. Review.

15.

Enzyme replacement therapy for lysosomal storage diseases.

Ohashi T.

Pediatr Endocrinol Rev. 2012 Oct;10 Suppl 1:26-34. Review.

PMID:
23330243
16.

Spinal cord compression in Maroteaux-Lamy syndrome: case report and review of the literature with effects of enzyme replacement therapy.

Jurecka A, Opoka-Winiarska V, Jurkiewicz E, Marucha J, Tylki-Szymańska A.

Pediatr Neurosurg. 2012;48(3):191-8. doi: 10.1159/000345635. Epub 2012 Dec 21. Review.

PMID:
23258111
17.

A multinational, multidisciplinary consensus for the diagnosis and management of spinal cord compression among patients with mucopolysaccharidosis VI.

Solanki GA, Alden TD, Burton BK, Giugliani R, Horovitz DD, Jones SA, Lampe C, Martin KW, Ryan ME, Schaefer MK, Siddiqui A, White KK, Harmatz P.

Mol Genet Metab. 2012 Sep;107(1-2):15-24. doi: 10.1016/j.ymgme.2012.07.018. Epub 2012 Jul 21. Review.

18.

Mucopolysaccharidosis type VI: a cardiologist's guide to diagnosis and treatment.

Golda A, Jurecka A, Opoka-Winiarska V, Tylki-Szymańska A.

Int J Cardiol. 2013 Jul 15;167(1):1-10. doi: 10.1016/j.ijcard.2012.05.115. Epub 2012 Jun 16. Review.

PMID:
22704873
19.

Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).

Golda A, Jurecka A, Tylki-Szymanska A.

Int J Cardiol. 2012 Jun 28;158(1):6-11. doi: 10.1016/j.ijcard.2011.06.097. Epub 2011 Jul 6. Review.

PMID:
21737154

Supplemental Content

Loading ...
Support Center